Le Lézard
Classified in: Health
Subjects: VET, CFG

Veterans Affairs Canada expands access to mental health services in Saskatoon


SASKATOON, Sept. 13, 2018 /CNW/ - When a Veteran is struggling with mental health and finds the courage to talk, timely access to mental health services is key. The Government of Canada is committed to ensuring Veterans and their families have access to the best possible assistance when and where they need it.

Today, the Honourable Seamus O'Regan, Minister of Veterans Affairs and Associate Minister of National Defence, joined Saskatchewan Health Authority's CEO Scott Livingstone for the opening of a new Operational Stress Injury (OSI) Satellite Service Site in Saskatoon, Saskatchewan. 

OSI Clinics and Satellite Service Sites provide specialized, evidence-based assessment, treatment and support services for operational stress injuries. Services are provided to Canadian Veterans, members of the Canadian Armed Forces (CAF), current and former members of the Royal Canadian Mounted Police (RCMP) and their families. Staff at these sites are trained in treating a range of mental health conditions such as post-traumatic stress disorder, anxiety, insomnia and depression.

Veterans Affairs Canada funds the Winnipeg Regional Health Authority (WRHA) to operate the Deer Lodge OSI Clinic. The new Saskatoon OSI Service Site is a satellite site of the Deer Lodge Clinic that will address the increased demand for OSI services in the province. This new arrangement between the WRHA and the Saskatchewan Health Authority will result in a team of clinicians operating out of the new site, which can be expanded as needed.

Quotes
"Veterans struggling with mental health shouldn't have to look far to find help. We've come so far in our understanding and treatment of mental health for Canada's serving members and Veterans but we must also ensure that those supports are available where and when they're needed. By opening this new site in Saskatoon, we are better able to provide the specialized treatments and supports, as well as educational programs and therapy, for Veterans and their families in Saskatchewan."
The Honourable Seamus O'Regan, Minister of Veterans Affairs and Associate Minister of National Defence

"We appreciate Veteran Affairs Canada's support in providing a new satellite site for this important service for Saskatchewan military, RCMP and Veterans. We hope that the expansion of this service into our province will allow these individuals and their families to continue on a path toward healing. Psychological injuries sustained while performing operational duties is something those of us in health care know is very real. This site is an important step forward in addressing mental health needs and we hope to learn from this site in order to enhance our own offerings of mental health supports."
Scott Livingstone, CEO Saskatchewan Health Authority

Quick Facts

Associated Links

 

SOURCE Veterans Affairs Canada


These press releases may also interest you

at 18:14
SARC (Sarcoma Alliance for Research Through Collaboration) is proud to announce the launch of the Sarcoma Centers Registry https://sarctrials.org/sarcoma-centers/, a comprehensive, global resource facilitating...

at 18:08
Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced with great respect and sorrow the unexpected passing last night of...

at 18:02
It takes a unique, special kind of dedication to become a nurse. For the nurses in First Nations and Inuit communities, it takes strength, resiliency, expertise, and most importantly, heart. It takes an understanding of the complex environment of...

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...



News published on and distributed by: